Skip to content

Study on the effect of different doses of rimazolam on bispectral index (BIS) during induction of general anesthesia in elderly patients

Study on the effect of different doses of rimazolam on bispectral index (BIS) during induction of general anesthesia in elderly patients

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2200059962
Enrollment
Unknown
Registered
2022-05-14
Start date
2022-05-02
Completion date
Unknown
Last updated
2024-04-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

General Anesthesia

Interventions

Experimental group:Rimazolam

Sponsors

Hangzhou Women's Hospital
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1. Age = 65 years; 2. ASA I-III; 3. Elective examination or operation under general anesthesia; 4. Body mass index (BMI) 18-30 kg/m2; 5. Sign the informed consent form, be able to accept the experimental method, and volunteer as the subject.

Exclusion criteria

Exclusion criteria: 1. Emergency surgery; 2. Remazolam is allergic or contraindicated; 3. Patients with preoperative disturbance of consciousness or chronic pain who use analgesics, psychotropic drugs and alcohol for a long time; 4. Have taken sedatives, antiemetics, antipruritic drugs 24 hours before operation or monoamine oxidase inhibitors or antidepressants within 15 days; 5. Any history of abnormal airway management of upper respiratory tract or respiratory insufficiency or sleep apnea that may cause dyspnea; 6. History of liver surgery, renal or liver insufficiency, gastrointestinal ulcer history or bleeding tendency; 7. Those who do not agree to participate or are participating in other drug trials; 8. Patients with tumor, serious cardio-cerebrovascular disease, etc.

Design outcomes

Primary

MeasureTime frame
bispectral index BIS;OAA/S;Blood pressure;Heart rate;

Countries

China

Contacts

Public ContactXiaodong Huang

Hangzhou Women's Hospital

350236963@qq.com+86 15068790428

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026